Abstract:Vaccines are one of the most effective strategies to prevent pathogen-induced illness in humans. The earliest vaccines were based on live inoculations with low doses of live or related pathogens, which carried a relatively high risk of developing the disease they were meant to prevent. The introduction of attenuated and killed pathogens as vaccines dramatically reduced these risks; however, attenuated live vaccines still carry a risk of reversion to a pathogenic strain capable of causing disease. This risk is completely eliminated with recombinant protein or subunit vaccines, which are atoxic and non-infectious. However, these vaccines require adjuvants and often significant optimization to induce robust T-cell responses and long-lasting immune memory. Some pathogens produce protein toxins that cause or contribute to disease. To protect against the effects of such toxins, chemically inactivated toxoid vaccines have been found to be effective. Toxoid vaccines are successfully used today at a global scale to protect against tetanus and diphtheria. Recent developments for toxoid vaccines are investigating the possibilities of utilizing recombinant protein toxins mutated to eliminate biologic activity instead of chemically inactivated toxins. Finally, one of the most contemporary approaches toward vaccine design utilizes messenger RNA (mRNA) as a vaccine candidate. This approach was used globally to protect against coronavirus disease during the COVID-19 pandemic that began in 2019, due to its advantages of quick production and scale-up, and effectiveness in eliciting a neutralizing antibody response. Nonetheless, mRNA vaccines require specialized storage and transport conditions, posing challenges for low- and middle-income countries. Among multiple available technologies for vaccine design and formulation, which technology is most appropriate? This review focuses on the considerable developments that have been made in utilizing diverse vaccine technologies with a focus on vaccines targeting bacterial toxins. We describe how advancements in vaccine technology, combined with a deeper understanding of pathogen-host interactions, offer exciting and promising avenues for the development of new and improved vaccines.

Immunomodulation using genetically engineered bacteria for type III-mediated delivery of heterologous antigens and cytokines: Potential application in vaccine and therapeutical developments

Engineering the type III secretion system in non-replicating bacterial minicells for antigen delivery

Mechanistic Insight into the TH1-Biased Immune Response to Recombinant Subunit Vaccines Delivered by Probiotic Bacteria-Derived Outer Membrane Vesicles

Exploiting bacterial-origin immunostimulants for improved vaccination and immunotherapy: current insights and future directions

A bacterial type III secretion-based protein delivery tool for broad applications in cell biology

Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria

Immunomodulation using bacterial enterotoxins

A systems approach to designing next generation vaccines: combining α-galactose modified antigens with nanoparticle platforms

Immune interface interference vaccines: An evolution‐informed approach to anti‐bacterial vaccine design

Engineering Escherichia coli into a Protein Delivery System for Mammalian Cells

Targeted Vaccine Adjuvants Based on Modified Cholera Toxin

Bactofection, Bacterial-Mediated Vaccination, and Cancer Therapy: Current Applications and Future Perspectives

Biomimetic bacterial and viral-based nanovesicles for drug delivery, theranostics, and vaccine applications

Immune Responses Elicited by Outer Membrane Vesicles of Gram-Negative Bacteria: Important Players in Vaccine Development

Current Status and Future Directions of Bacteria-Based Immunotherapy

Bacillus subtilis as a tool for vaccine development: from antigen factories to delivery vectors

Recent Developments in Vaccine Design: From Live Vaccines to Recombinant Toxin Vaccines

Recombinant lactic acid bacteria as delivery vectors of heterologous antigens: the future of vaccination?

Type 5 secretion system antigens as vaccines against Gram-negative bacterial infections

Metabolic Engineering of Salmonella Vaccine Bacteria To Boost Human Vγ2Vδ2 T Cell Immunity

Delivery of foreign antigens by engineered outer membrane vesicle vaccines